Fresh analysis indicates that people who stop using new slimming jabs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Published data in a leading health publication demonstrates that while overweight people can lose a large proportion of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Users using such treatments must be aware of the danger of rapid rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
This pace of recovery implies a reversion to starting mass in about one and a half years.
Comparing Therapies
The research, which examined 37 of trials involving thousands of participants, compared the outcomes of GLP-1 agonists with older methods.
Scientists point out that individuals who shed pounds through dieting usually see a slower weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Doctors propose the mode of action of the drugs accounts for the heightened weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations far above than normal could lead to the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making binge eating much more probable."
A Lifelong Condition?
Medical guidelines suggest the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the high risk of relapse, the treatment is often ongoing.
This perspective is reinforced by pharmaceutical companies, who say that the findings "emphasize the persistent nature of excess weight," comparing it to managing conditions like hypertension.
User Experiences
People who have stopped the jabs report a powerful return of cravings.
"It felt as if a switch that goes on and I was suddenly starving," described a patient.
This challenge is worsened if individuals have not developed lasting lifestyle or habit modifications during therapy.
Growing Use
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is greater among females compared to males.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and maintained weight loss relies on combined behavioural support.
